丁雯, 丁黎, 李文博, 潘虹, 林宏达. 地夫可特片在健康中国受试者体内药代动力学研究J. 药学学报, 2014,49(6): 921-926.
引用本文: 丁雯, 丁黎, 李文博, 潘虹, 林宏达. 地夫可特片在健康中国受试者体内药代动力学研究J. 药学学报, 2014,49(6): 921-926.
DING Wen, DING Li, LI Wen-bo, PAN Hong, LIN Hong-da. Pharmacokinetics of deflazacort tablets in healthy Chinese volunteersJ. Acta Pharmaceutica Sinica, 2014,49(6): 921-926.
Citation: DING Wen, DING Li, LI Wen-bo, PAN Hong, LIN Hong-da. Pharmacokinetics of deflazacort tablets in healthy Chinese volunteersJ. Acta Pharmaceutica Sinica, 2014,49(6): 921-926.

地夫可特片在健康中国受试者体内药代动力学研究

Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers

  • 摘要: 地夫可特为前体药物,口服给药后迅速吸收并代谢为活性产物21-羟基地夫可特(21-OH DFZ)。本文研究健康中国受试者单次和多次口服地夫可特片后21-OH DFZ的药代动力学特征。12名健康受试者,男女各半,按3 × 3拉丁方设计分别餐后单次交叉口服地夫可特片6、12和24 mg,两次服药间的清洗期为1周。三周期单次给药结束后,经过1周清洗期进行多次给药试验,每日一次餐后口服地夫可特片12 mg,连续服药7天。受试者餐后单次口服地夫可特片6、12和24 mg后21-OH DFZ的Cmax分别为(37.7 ± 11.6)、(61.5 ± 17.7)和(123 ± 23)ng·mL-1t1/2分别为(1.90 ± 0.32)、(1.96 ± 0.27)和(2.13 ± 0.34)h,AUC0-14 h分别为(96.6 ± 25.9)、(190 ± 44)和(422 ± 107)ng·h·mL-1。多次给药达稳态后,21-OH DFZ的稳态平均血药浓度Cav为(7.00 ± 1.66)ng·mL-1,稳态血药浓度波动度DF为7.7 ± 1.2。结果表明,口服地夫可特片6~24 mg剂量内,21-OH DFZ在健康受试者体内呈线性药动学特征,药动学特征不存在性别差异,多次给药后药物在体内无蓄积。

     

    Abstract: Deflazacort (DFZ, a prodrug) is well absorbed and rapidly metabolized into the active metabolite 21-hydroxydeflazacort (21-OH DFZ) after oral administration.The aim of this study is to evaluate thepharmacokinetic properties of 21-OH DFZ in healthy Chinese volunteers after a single and multiple oraladministration of DFZ tablets under fed condition.Twelve volunteers (six males and six females) were administered a single dose of 6 mg or 12 mg or 24 mg of DFZ in three different periods separately, accordingto the 3 × 3 Latin square design.Between each administration period there was a washout period of one week.The multiple-dose study of 12 mg dose DFZ per day for 7 consecutive days was started after a 1 w washoutperiod when the single-dose study completed.The pharmacokinetic parameters of 21-OH DFZ after the single oral administration of 6 mg, 12 mg and 24 mg DFZ tablets were as follows: (37.7 ± 11.6), (61.5 ± 17.7) and(123 ± 23) ng·mL-1 for Cmax; (1.90 ± 0.32), (1.96 ± 0.27) and (2.13 ± 0.34) h for t1/2; (96.6 ± 25.9), (190 ± 44) and (422 ± 107) ng·h·mL-1 for AUC0-14 h, respectively.After the multiple dose administration, the mean plasmaconcentration at steady-state Cav was (7.00 ± 1.66) ng · mL-1 and the degree of plasma concentration fluctuation DF was 7.7 ± 1.2.The results showed that the pharmacokinetic characteristics of 21-OH DFZ in healthy Chinese volunteers were linear over the dose range of 6 to 24 mg.No significant gender differences were found in the pharmacokinetics of 21-OH DFZ in healthy Chinese volunteers.After the multiple dose administration of 12 mg DFZ for 7 d, no accumulation of 21-OH DFZ in healthy Chinese volunteers was observed.

     

/

返回文章
返回